Cancer Supportive Care Products Market to 2016

1. Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

2. The Global Cancer Supportive Care Products Market is Expected to Witness Sluggish Annual Growth of 2% between 2009 and 2016 In 2009, the global cancer supportive care products market was valued at $11 billion, up from $7.5 billion in 2001, indicating a CAGR (Compounded Annual Growth Rate) of 5% between 2001 and 2009. The major drivers of the growth had been the launch of new and better treatment medications, increased prevalence of cancer and a resulting increase in chemotherapy patient populations. In future, the global cancer supportive care products market is expected to reach $12.6 billion, indicating a CAGR of 2% during the period 2009-2016. The market will grow until 2014 at a growth rate of approximately 3- 5%, followed by a decline of approximately 1.2% until 2016 due to the patent expiry of leading drugs across all major markets. Some of the major drugs that are expected to lose patent protection between 2013 and 2016 include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Procrit (epoetin alfa), Emend (aprepitant), Zometa (zoledronic acid) and Aloxi (palonosetron hydrochloride). Thus, patent expiries coupled with a weak development pipeline will be the major factors behind the sluggish growth of the cancer supportive care products market in future.

3. Growth in the Bone Metastases, Oral Mucositis and Dry Mouth, and Cancer Pain Markets will Drive the Future Market Growth Bone metastases, oral mucositis and dry mouth, and cancer pain therapeutics are the sectors estimated to demonstrate significant growth in future among all the segments of the global cancer supportive care products market. Between 2009 and 2016, the bone metastases therapeutics market will be the fastest growing market segment, and is expected to reach $1.2 billion in 2016 from $690m in 2009, indicating a CAGR of 8.1%. Increased uptake of novel monoclonal antibody, Xgeva (denosumab), which received approval for bone metastases in cancer patients in November 2010, is expected to be the principal driver for the market. In addition, an increasing prevalence population is also expected to drive the market in future. On the other hand, the oral mucositis and dry mouth therapeutics market is expected to witness a CAGR of 5.9% between 2009 and 2016 to reach $2.1 billion in 2016 from $1.4 billion in For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Cancer-Supportive-Care-Products-Market-to-2016-Market-is-Expected-to-Decline-Due-to-Generic-Erosion-and-Entry-of-Biosimilars&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

4. 2009. High unmet need in terms of efficacious drugs and the increasing prevalence of the disease are expected to be the major drivers of the global oral mucositis and dry mouth therapeutics market in future. The cancer pain therapeutics market will witness a CAGR of 5.3% between 2009 and 2016, driven by increasing prescription rates and new modes of delivery of cancer pain drugs that will help in the better management of pain for a longer duration. These factors are expected to drive the global cancer pain therapeutics market from $2 billion in 2009 to $2.9 billion in 2016. Weak Pipeline with Very Few Promising Molecules Will Lead to Increased Dominance of Biosimilars in the Market after the Patent Expiry of Leading Biologics The current cancer supportive care therapeutics pipeline is weak, with very few promising molecules in the late stages of development. In terms of phases, Phase III accounts for approximately one-third of the global cancer supportive care pipeline, while Phase II molecules account for 39%. Four compounds are in the regulatory filing stage. However, a large majority of these drugs are either me-too, combination therapies of existing drugs, or new formulations. Therefore, in spite of having 38% of the pipeline in the late stages of drug development, the cancer supportive care products market is not expected to witness any major drug launches in the near future. In the entire pipeline, there are only five to six

5. major novel promising compounds, a scenario which does not suggest strong future market growth. Thus, the weak development pipeline is expected to be one of the major factors that are expected to restrict the growth of the future cancer supportive care products market. Emerging Pharmaceutical Geographies Dominate As Areas of Concentration in the M&A and Licensing Deals for Cancer Supportive Care Products Market Between 2008 and 2010, a significant majority of the M&A (Mergers & Acquisitions) and licensing deals concentrated on emerging geographies such as Asia-Pacific, MEA (Middle East and Africa) and SCA (South and Central America). Asia-Pacific was one of the regions of concentration in 55% of the total number of deals. On the other hand, MEA and SCA each formed part of 18% of the deals. A total of 39% of the deals had North America as their geographic concentration, while only 20% of the deals concentrated on Europe. Thus, in future, emerging geographies are expected to dominate as the major areas of focus for the pharmaceutical companies when it comes to M&A and licensing agreements. One of the major reasons for this is expected to be the

6. leading companies’ strategies of expanding into newer markets with their existing products. Also, through partnering with generic companies in the developing geographies to market their product the pharmaceutical companies expect to gain greater market share in the generics-dominated markets of these regions. GBI Research, the leading business intelligence provider, has released its latest research, “Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars”, which provides insights into the cancer supportive care products market and forecasts until 2016. The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition,

7. the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Cancer-Supportive-Care-Products-Market-to-2016-Market-is-Expected-to-Decline-Due-to-Generic-Erosion-and-Entry-of-Biosimilars&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.gbiresearch.com

8. For more details contact: pressreleases@gbiresearch.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782